Invention Grant
- Patent Title: Cancer stem cell growth inhibitor using miRNA
-
Application No.: US16498986Application Date: 2018-03-30
-
Publication No.: US11439657B2Publication Date: 2022-09-13
- Inventor: Xin Wu , Masaki Mori , Hirofumi Yamamoto
- Applicant: CancerStem Tech Inc.
- Applicant Address: JP Ibaraki
- Assignee: CancerStem Tech Inc.
- Current Assignee: CancerStem Tech Inc.
- Current Assignee Address: JP Ibaraki
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: JPJP2017-066599 20170330
- International Application: PCT/JP2018/013560 WO 20180330
- International Announcement: WO2018/181877 WO 20181004
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; A61K31/7105 ; A61P35/00 ; C12N15/113 ; A61K45/06

Abstract:
The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.
Public/Granted literature
- US20210052627A1 CANCER STEM CELL GROWTH INHIBITOR USING miRNA Public/Granted day:2021-02-25
Information query